Boston Scientific Corporation (BSX) Paying Up to $425 Million for Vessix Vascular, Inc.
11/8/2012 7:05:44 AM
More...
|
Vessix Vascular, Inc. to Present 3-Month, 6-Month Results From REDUCE-HTN Renal Denervation Clinical Study at TCT
10/22/2012 10:30:11 AM
More...
|
Vessix Vascular, Inc. Receives CE Mark for V2 Renal Denervation System™ for Treatment of Hypertension
5/1/2012 8:37:23 AM
More...
|
Vessix Vascular, Inc. Names Michael D. Gioffredi Chief Commercialization Officer
4/12/2012 10:01:17 AM
More...
|
First Patients Treated in Hypertension Clinical Study Using the Vessix Vascular, Inc. Balloon Catheter Renal Denervation System
2/24/2012 9:28:33 AM
More...
|
Vessix Vascular, Inc. to Present V2 Renal Denervation System(TM) for Hypertension at TRenD Workshop 2012
2/13/2012 9:44:54 AM
More...
|